Drug Trial Radar · NCT03725722
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Dec 28, 2018
Primary completion
May 19, 2020
Study completion May 19, 2020
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
Delgocitinib creamDrug
Cream for topical application
Delgocitinib cream vehicleDrug
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.Time frame: Week 0 to Week 8
Locations
31 sites in 3 countries. Site status is shown where the registry gives one.
Leo Pharma Investigational Site
Birmingham, Alabama
Leo Pharma Investigational Site
Encino, California
Leo Pharma Investigational Site
Los Angeles, California
Leo Pharma Investigational Site
Los Angeles, California
Leo Pharma Investigational Site
Rolling Hills Estates, California
Leo Pharma Investigational Site
Santa Ana, California
Leo Pharma Investigational Site
Chicago, Illinois
Leo Pharma Investigational Site
Detroit, Michigan
Leo Pharma Investigational Site
New York, New York
Leo Pharma Investigational Site
High Point, North Carolina
Leo Pharma Investigational Site
Philadelphia, Pennsylvania
Leo Pharma Investigational Site
Carlton, Australia
Leo Pharma Investigational Site
Darlinghurst, Australia
Leo Pharma Investigational Site
East Melbourne, Australia
Leo Pharma Investigational Site
Hectorville, Australia
Leo Pharma Investigational Site 1
Kogarah, Australia
Leo Pharma Investigational Site
Kogarah, Australia
Leo Pharma Investigational Site
Woolloongabba, Australia
Leo Pharma Investigational Site
Calgary, Alberta, Canada
Leo Pharma Investigational Site
Edmonton, Alberta, Canada
Leo Pharma Investigational Site
Surrey, British Columbia, Canada
Leo Pharma Investigational Site
Winnipeg, Manitoba, Canada
Leo Pharma Investigational Site
Fredericton, New Brunswick, Canada
Leo Pharma Investigational Site
Mississauga, Ontaria, Canada
Leo Pharma Investigational Site
Barrie, Ontario, Canada
Leo Pharma Investigational Site
Markham, Ontario, Canada
Leo Pharma Investigational Site
Peterborough, Ontario, Canada
Leo Pharma Investigational Site
Richmond Hill, Ontario, Canada
Leo Pharma Investigational Site
Toronto, Ontario, Canada
Leo Pharma Investigational Site
Toronto, Ontario, Canada
Leo Pharma Investigational Site
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.